SEARCH:   Advanced

Blood, 15 March 2007, Vol. 109, No. 6, pp. 2604-2606. Prepublished online as a Blood First Edition Paper on November 30, 2006; DOI 10.1182/blood-2006-09-046409. This Article Full Text Full Text (PDF) Supplemental Case Studies All Versions of this Article: blood-2006-09-046409v1 109/6/2604    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chanan-Khan, A. A. Articles by Singhal, S. Search for Related Content PubMed PubMed Citation Articles by Chanan-Khan, A. A. Articles by Singhal, S. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief Report Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study Asher A. Chanan-Khan1, Jonathan L. Kaufman2, Jayesh Mehta3, Paul G. Richardson4, Kena C. Miller1, Sagar Lonial2, Nikhil C. Munshi4, Robert Schlossman4, Joseph Tariman3, and Seema Singhal3 1 Roswell Park Cancer Institute, Buffalo, NY; 2 Emory University, Atlanta, GA; 3 Northwestern University, Chicago, IL; 4 Dana-Farber Cancer Institute, Boston, MA Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. A. Hutchison, A. R. Bradwell, M. Cook, K. Basnayake, S. Basu, S. Harding, J. Hattersley, N. D. Evans, M. J. Chappel, P. Sampson, et al. Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 745 - 754. [Abstract] [Full Text] [PDF] E. Terpos, E. Katodritou, E. Tsiftsakis, E. Kastritis, D. Christoulas, A. Pouli, E. Michalis, E. Verrou, K. Anargyrou, K. Tsionos, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration Haematologica, March 1, 2009; 94(3): 372 - 379. [Abstract] [Full Text] [PDF] E. Kastritis, M. Migkou, M. Gavriatopoulou, P. Zirogiannis, V. Hadjikonstantinou, and M. A. Dimopoulos Treatment of light chain deposition disease with bortezomib and dexamethasone Haematologica, February 1, 2009; 94(2): 300 - 302. [Full Text] [PDF] J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766. [Abstract] [Full Text] [PDF] R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF] E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica, October 1, 2007; 92(10): 1351 - 1358. [Abstract] [Full Text] [PDF] H. Ludwig, J. Drach, H. Graf, A. Lang, and J. G. Meran Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma Haematologica, October 1, 2007; 92(10): 1411 - 1414. [Abstract] [Full Text] [PDF] R. Manochakian, K. C. Miller, and A. A. Chanan-Khan Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma Oncologist, August 1, 2007; 12(8): 978 - 990. [Abstract] [Full Text] [PDF] P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson New Drugs for Myeloma Oncologist, June 1, 2007; 12(6): 664 - 689. [Abstract] [Full Text] [PDF] P. Richardson, C. Mitsiades, R. Schlossman, I. Ghobrial, T. Hideshima, D. Chauhan, N. Munshi, and K. Anderson The Treatment of Relapsed and Refractory Multiple Myeloma Hematology, January 1, 2007; 2007(1): 317 - 323. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020